ASP3082 + docetaxel

ASP3082 + docetaxel is an investigational combination regimen comprising **ASP3082**, a first-in-class KRAS G12D degrader, and **docetaxel**, a well-established microtubule inhibitor chemotherapeutic agent. ASP3082 uses proteolysis-targeting chimera (PROTAC) technology, binding specifically to KRAS G12D mutant proteins and an E3 ubiquitin ligase, inducing targeted ubiquitination and proteasome-mediated degradation of KRAS G12D, with tumor-suppressive effects in cancers harboring this mutation[2][4]. The combination is being evaluated in clinical trials for advanced solid tumors with KRAS G12D mutations, aiming to improve antitumor efficacy through synergistic targeted degradation and cytotoxic chemotherapy[1][4]. Docetaxel acts by stabilizing microtubules and inhibiting their depolymerization, leading to arrest of cell division and apoptosis.